Dong-A Socio Holdings Co Ltd (000640):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Dong-A Socio Holdings Co Ltd (000640) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9886
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Dong-A Socio Holdings Co Ltd (Dong-A Socio Holdings), formerly Dong-A Pharmaceutical Co., Ltd., offers business management services. It is a subsidiary of Dong-A Socio Group. It operates in various markets such as pharmaceuticals, food and beverages, logistics, IT, and materials. The group focuses on new business investments, development of biomedicines and research and development of new innovative drugs. Its main business areas include the manufacture of over-the-counter (OTC) and ethical drugs (ETC). Its major products include Bacchus-F, Bacchus-D, Panpyrin, Benachio, Myvlart Tab, Tempo and Eyebon. It also manufactures active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. Dong-A Socio Holdings is headquartered in Seoul, South Korea.

Dong-A Socio Holdings Co Ltd (000640) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Dong-A ST Extends Licensing Agreement with Eurofarma 12
Kaken Pharma Enters into Distribution Agreement with Dong-A ST 13
CrystalGenomics Enters into Agreement with Dong-A ST for Acelex 14
Dong-A ST Enters Into Co-Marketing Agreement With Huons For Nenoma 15
Licensing Agreements 16
Dong-A ST Enters into Licensing Agreement with Takara Bio 16
Neurobo Pharma Enters into Licensing Agreement with Dong-A ST 17
Rooyan Darou Pharma Enters into Agreement with Dong-A ST 18
Tabuk Pharma Enters into Licensing Agreement with Dong-A ST for Zydena 19
AbbVie Enters into Licensing Agreement with Dong-A ST 20
Dong-A ST Enters into Licensing Agreement with Beactica 21
ST Pharm Enters into Technology Transfer Agreement with KRICT 22
Tobira Therapeutics Enters into Licensing Agreement with Dong-A for Evogliptin 23
Dong-A Enters into Licensing Agreement with Tobira Therapeutics for Cenicriviroc 25
Geropharm Enters into Licensing Agreement with Dong-A ST 26
Asahi Kasei Pharma Enters into License Agreement with Dong-A ST 27
Dong-A Pharma Enters Into Licensing Agreement With Alkem Labs For DA-1229 28
Sanwa Kagaku Kenkyusho Enters into Licensing Agreement with Dong-A ST 29
Luye Pharma Group Enters Into Licensing Agreement With Dong-A Pharma For DA-1229 30
Equity Offering 31
ST Pharm to Raise USD113 Million in IPO 31
Dong-A Pharma Spin-Off Dong-A ST 32
Acquisition 33
Dong-A Socio to Acquire Shares of ST Pharm for USD157 Million in Tender Offer 33
Dong-A Socio to Divest Stake in DMB 34
Dong-A Pharmaceutical Mulling Acquisition of Spain’s Invent Farma 35
Dong-A Socio Holdings Co Ltd – Key Competitors 36
Dong-A Socio Holdings Co Ltd – Key Employees 37
Dong-A Socio Holdings Co Ltd – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Joint Venture 38
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Dong-A Socio Holdings Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Dong-A ST Extends Licensing Agreement with Eurofarma 12
Kaken Pharma Enters into Distribution Agreement with Dong-A ST 13
CrystalGenomics Enters into Agreement with Dong-A ST for Acelex 14
Dong-A ST Enters Into Co-Marketing Agreement With Huons For Nenoma 15
Dong-A ST Enters into Licensing Agreement with Takara Bio 16
Neurobo Pharma Enters into Licensing Agreement with Dong-A ST 17
Rooyan Darou Pharma Enters into Agreement with Dong-A ST 18
Tabuk Pharma Enters into Licensing Agreement with Dong-A ST for Zydena 19
AbbVie Enters into Licensing Agreement with Dong-A ST 20
Dong-A ST Enters into Licensing Agreement with Beactica 21
ST Pharm Enters into Technology Transfer Agreement with KRICT 22
Tobira Therapeutics Enters into Licensing Agreement with Dong-A for Evogliptin 23
Dong-A Enters into Licensing Agreement with Tobira Therapeutics for Cenicriviroc 25
Geropharm Enters into Licensing Agreement with Dong-A ST 26
Asahi Kasei Pharma Enters into License Agreement with Dong-A ST 27
Dong-A Pharma Enters Into Licensing Agreement With Alkem Labs For DA-1229 28
Sanwa Kagaku Kenkyusho Enters into Licensing Agreement with Dong-A ST 29
Luye Pharma Group Enters Into Licensing Agreement With Dong-A Pharma For DA-1229 30
ST Pharm to Raise USD113 Million in IPO 31
Dong-A Pharma Spin-Off Dong-A ST 32
Dong-A Socio to Acquire Shares of ST Pharm for USD157 Million in Tender Offer 33
Dong-A Socio to Divest Stake in DMB 34
Dong-A Pharmaceutical Mulling Acquisition of Spain's Invent Farma 35
Dong-A Socio Holdings Co Ltd, Key Competitors 36
Dong-A Socio Holdings Co Ltd, Key Employees 37
Dong-A Socio Holdings Co Ltd, Subsidiaries 38
Dong-A Socio Holdings Co Ltd, Joint Venture 38

List of Figures
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Dong-A Socio Holdings Co Ltd (000640):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • RayBiotech Inc-製薬・医療分野:企業M&A・提携分析
    Summary RayBiotech Inc (RayBiotech) is a life science company that offers proteins, antibodies and immunological kits. The company’s products include antibody arrays, elisa, functional assays, antibodies and custom recombinant protein service. It provides services such as testing services, custom se …
  • Oxford Nanopore Technologies Ltd-医療機器分野:企業M&A・提携分析
    Summary Oxford Nanopore Technologies Ltd (Oxford Nanopore), formerly Oxford NanoLabs Ltd., is a biotechnology diagnostic company. It develops technologies for molecular detection and analysis. The company offers a range of nanopores and devices such as MinION, PromethION and GridION used for the ana …
  • Hatch Ltd:企業の戦略的SWOT分析
    Hatch Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Pharmaceutical Product Development LLC:企業の戦略的SWOT分析
    Pharmaceutical Product Development LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • Grupo Televisa S.A.B.:企業の戦略・SWOT・財務情報
    Grupo Televisa S.A.B. - Strategy, SWOT and Corporate Finance Report Summary Grupo Televisa S.A.B. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Societe Des Bains De Mer Sa:企業の戦略・SWOT・財務分析
    Societe Des Bains De Mer Sa - Strategy, SWOT and Corporate Finance Report Summary Societe Des Bains De Mer Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Monitise plc:企業のM&A・事業提携・投資動向
    Monitise plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Monitise plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Lexmark International Inc:医療機器:M&Aディール及び事業提携情報
    Summary Lexmark International Inc (Lexmark) a subsidiary of Ninestar Corp., provider of imaging and printing solutions. It manufactures, develops and supplies printing and imaging solutions, managed print services, device management, document workflow, business process and content management solutio …
  • Korean Reinsurance Company:企業の戦略・SWOT・財務情報
    Korean Reinsurance Company - Strategy, SWOT and Corporate Finance Report Summary Korean Reinsurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • SmartCool Systems Inc (SSC):企業の財務・戦略的SWOT分析
    Summary SmartCool Systems Inc (SmartCool Systems) is a clean technology company that manufactures and sells energy and cost reduction technologies. The company’s products include ECO3, ESM, and soft solutions. Its ECO3 and ESM are retrofit technologies that reduce the energy consumption of compresso …
  • Ethicon US LLC:医療機器:M&Aディール及び事業提携情報
    Summary Ethicon US LLC (Ethicon), a subsidiary of Johnson and Johnson, is a medical equipment company which operates through Ethicon Inc, and Ethicon Endo-Surgery Inc. It develops and markets surgical instruments and devices. Its major products include staplers, energy devices, clip appliers, trocar …
  • Solasia Pharma KK (4597)-製薬・医療分野:企業M&A・提携分析
    Summary Solasia Pharma KK (Solasia Pharma) formerly JapanBridge Inc is a healthcare service provider that provides patient access to Western oncology therapies. The company develops and commercializes oncology therapies and cancer supportive care products. Its products include transdermal system whi …
  • Ebara Corp (6361):企業の財務・戦略的SWOT分析
    Ebara Corp (6361) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Commercial International Bank (Egypt) SAE:企業の戦略・SWOT・財務情報
    Commercial International Bank (Egypt) SAE - Strategy, SWOT and Corporate Finance Report Summary Commercial International Bank (Egypt) SAE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Pathway Genomics Corp-医療機器分野:企業M&A・提携分析
    Summary Pathway Genomics Corp (Pathway Genomics) is a healthcare laboratory that offers genetic testing services to physicians and their patients with actionable and accurate precision healthcare information to improve health and wellness. Its tests comprise liquid biopsy cancer intercept, true here …
  • Exponent Inc (EXPO):企業の財務・戦略的SWOT分析
    Summary Exponent Inc (Exponent), formerly Failure Analysis Associates Inc, is an engineering and scientific consulting company that provides technical solutions. The company provides engineering services in biomechanics, buildings and structures, biomedical engineering, civil engineering, electrical …
  • Mereo Biopharma Group Plc (MPH):企業の財務・戦略的SWOT分析
    Summary Mereo Biopharma Group Plc (Mereo), formerly Mereo Biopharma Group Ltd is a specialty bio-pharmaceutical company which develops novel medicines for the treatment of rare and specialty diseases. The company’s pipeline products include BPS-804, which is used for the treatment of brittle bone sy …
  • Marksmen Energy Inc (MAH):石油・ガス:M&Aディール及び事業提携情報
    Summary Marksmen Energy Inc (Marksmen Energy), formerly Marksmen Resources Ltd is an oil and gas exploration and development company that explores and develops light oil assets in Ohio. The company acquires, explores, operates, mines, manages, produces and develops oil and gas properties in Western …
  • Stealth BioTherapeutics Corp (MITO):企業の戦略的SWOT分析
    Stealth BioTherapeutics Corp (MITO) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Henderson Land Development Co Ltd:企業の戦略・SWOT・財務情報
    Henderson Land Development Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Henderson Land Development Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆